Drug Monograph

Drug/Drug Class:	**Ilaris® (canakinumab) solution for injection/ Interleukin – 1B Blocking Agent**
Prepared for:	MO HealthNet
Prepared by:	Conduent-Heritage

☒ **New Criteria** ☐ **Revision of Existing Criteria**

Executive Summary

Purpose:	The purpose of this monograph is to provide a review of new therapy to determine whether the reviewed drug should be made available on an open access basis to prescribers, require a clinical edit or require prior authorization for use.
Dosage Forms:	Ilaris® is now available in a preservative free solution for injection that contains 150 mg canakinumab per ml. This solution does not have to be reconstituted compared to previous dosage forms.
Manufacturer:	Novartis Pharmaceuticals Corporation, East Hanover, NJ 07936
Indications:	Ilaris® is an interleukin-1B blocker indicated for the treatment of the following auto inflammatory Periodic Fever Syndromes: Cryopyrin-Associated Periodic Syndrome (CAPS), Tumor Necrosis Factor Receptor Associated Periodic Syndrome (TRAPS), Hyperimmunoglobulin D Syndrome (HIDS)/Mevalonate Kinase Deficiency (MKD), and Familial Mediterranean Fever (FMF). It is also indicated for the treatment of active Systemic Juvenile Idiopathic Arthritis (SJIA) in patients aged 2 years and older.
Costs:	$16,215.56 per vial of Ilaris® solution. Maximum Allowable Cost
Summary of Findings:	This drug is being considered for inclusion in the state specific Preferred Drug List (PDL) for Cryopyrin-Associated Periodic Syndrome (CAPS)..
Status Recommendation:	☐ Prior Authorization (PA) Required ☐ Open Access ☐ Fiscal Edit ☒ PDL
Type of PA Criteria:	☐ Increased Risk of ADE ☒ Under Solicitation ☐ Appropriate Indications ☐ Non Preferred

Prepared By: Luke Boehmer Pharm.D.
Date: May 24, 2017